Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: A feasibility study

Pharmacological Research

Volumn 42, Issue 2, 2000, Pages 151-156

  Westermann, A M ^a   Taal, B G ^a   Swart, M ^a   Boot, H ^a   Craanen, M ^a   Gerritsen, W R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Chemotherapy sequencing; Chemotherapy toxicity; Doxorubicin; Gastric cancer; Growth factors

Indexed keywords

DOXORUBICIN; FLUOROURACIL; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG MEGADOSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; STOMACH CANCER;

EID: 0033837086     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2000.0677     Document Type: Article

References (22)

1. Improving survival in gastric cancer: Review of 5-year survival rates in English language publications from 1970
2. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group
3. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: Five-year follow-up
4. Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials
5. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer
6. Neoadjuvant therapy of high-risk gastric cancer: A phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil
7. Hepatic resection for metastatic tumours from gastric cancer: Analysis of prognostic factors
8. High-dose chemotherapy with autologous bone marrow transplantation in the treatment of advanced gastric cancer
9. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer
10. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
11. Chemotherapeutic protocol in the treatment of metastasising gastric carcinoma: Methotrexate, adriamycin and 5-fluorouracil [German]
12. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - A step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group
13. FAMTX versus etoposide, doxorubicin and cisplatin: A random assignment trial in gastric cancer
14. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophago-gastric cancer
15. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leukovorin, glutathione, and filgrastim: A report from the Italian Group for the Study of Digestive Tract Cancer
16. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial
17. Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil
18. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism
19. 5-Fluorouracil plus tauromustine in advanced colorectal cancer: Unexpected negative results
20. Tauromustine (TCNU) combined with 5-fluorouracil and leukovorin in the treatment of advanced colon cancer
21. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer
22. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer